WntResearch AB (publ) 556738-7864 Press release 2015-12-21 WntResearch: Swedish site will participate in the Foxy-5 phase 1b study WntResearch today announces that the Department of Oncology and the Clinical Trial Unit (Phase I), R&D Centre, Skåne University Hospital Lund have agreed to participate as a site in the clinical phase 1b study with Foxy-5. The phase 1b study will be initiated as soon as the study application has been approved (see press release 2015-12-14). Nils Brünner, CEO: “We are very happy to extend the number of clinical sites for the upcoming phase 1b study with a Swedish site. This ought to result in a more efficient recruitment of patients into the study.” For additional information please contact: Nils Brünner, CEO E-mail: [email protected] Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.